<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311424</url>
  </required_header>
  <id_info>
    <org_study_id>17378</org_study_id>
    <secondary_id>I8F-MC-GPHX</secondary_id>
    <secondary_id>2019-003664-44</secondary_id>
    <nct_id>NCT04311424</nct_id>
  </id_info>
  <brief_title>Study of Tirzepatide in Healthy Participants</brief_title>
  <official_title>Disposition of [14C]-Tirzepatide Following Subcutaneous Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at how much tirzepatide gets into the bloodstream and&#xD;
      how long the body takes to get rid of it. This study will involve a single dose of 14C&#xD;
      radiolabelled tirzepatide. This means that a radioactive tracer substance, C14, will be&#xD;
      incorporated into the study drug to investigate the study drug and its breakdown products and&#xD;
      to find out how much of these pass from blood into urine, feces and expired air.&#xD;
&#xD;
      Screening is required within 28 days prior to the start of the study. For each participant,&#xD;
      the total duration of the clinical trial will be approximately 15 weeks, including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Actual">October 2, 2020</completion_date>
  <primary_completion_date type="Actual">October 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Pre-dose and up to 63 days post-dose</time_frame>
    <description>Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Pre-dose and up to 63 days post-dose</time_frame>
    <description>Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Number of Metabolites</measure>
    <time_frame>Pre-dose and up to 63 days post-dose</time_frame>
    <description>Total Number of Metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable)</measure>
    <time_frame>Pre-dose and up to 63 days post-dose</time_frame>
    <description>Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Tirzepatide</measure>
    <time_frame>Pre-dose and up to 63 days post-dose</time_frame>
    <description>PK: AUC(0-∞) of Tirzepatide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of Tirzepatide</measure>
    <time_frame>Pre-dose and up to 63 days post-dose</time_frame>
    <description>PK: Cmax of Tirzepatide</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>14C Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of [14C]-tirzepatide administered subcutaneously (SC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C Tirzepatide</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>14C Tirzepatide</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Overtly healthy males as determined by medical history, physical examination, and&#xD;
             other screening procedures&#xD;
&#xD;
          -  Have a body mass index (BMI) between 18.0 to 32.0 kilograms per meter squared (kg/m²),&#xD;
             inclusive at screening&#xD;
&#xD;
          -  Are willing to be available for the full duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have known allergies to tirzepatide or related compounds&#xD;
&#xD;
          -  Have a medical condition or medical history that makes participation in the study&#xD;
             unsafe or which may interfere in the interpretation of the results of the study&#xD;
&#xD;
          -  Have had exposure to significant radiation within 12 months prior to dosing (for&#xD;
             example, multiple x-ray or computed tomography [CT] scans, barium meal, being employed&#xD;
             in a job requiring radiation exposure monitoring)&#xD;
&#xD;
          -  Have participated in any clinical trial involving a radiolabeled substance within the&#xD;
             past 12 months&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Ltd</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 15, 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>October 16, 2020</last_update_submitted>
  <last_update_submitted_qc>October 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirzepatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

